BioInvent International AB (publ) (BINVS.XC)
| Previous Close | 28.50 |
| Open | 29.90 |
| Bid | 27.10 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 27.45 - 29.90 |
| 52 Week Range | 27.45 - 34.75 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 1.843B |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings Date | Aug 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREBioInvent Gains Patent for BI-1808 in China
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...
- ACCESSWIRE
BioInvent to Host Virtual KOL Event to Highlight Recently Presented Efficacy Data from BioInvent's Lead Candidates BI-1808 and BI-1206
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company ...
- ACCESSWIRE
BioInvent to Host Virtual KOL Event on June 18, 2024, to Discuss BioInvent's Lead Candidates BI-1808 and BI-1206
LUND, SWEDEN / ACCESSWIRE / May 24, 2024 / BioInvent International (STO:BINV) TNFR2 and FcyRIIB are promising targets in immuno-oncology. BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery ...
